SAN DIEGO, Aug. 5, 2015 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional
biology company focused on delivering breakthrough 3D bioprinting
technology, today announced that its financial results for the
first quarter of fiscal year 2016 will be released Monday,
August 10, 2015.
The Company will host a conference call at 5:00 p.m.
ET to discuss the financial results. If you would like
to participate in the call, please dial-in approximately 10
minutes prior to the start time, and ask to join the Organovo
Holdings, Inc. conference call. The dial-in info is as
follows:
Participant dial in
(toll free):
|
1-888-317-6003
|
Participant
international dial in:
|
1-412-317-6061
|
EE TF -
Canada
|
1-866-284-3684
|
You will need to provide the Participant Elite Entry Number:
4892967
A replay will be made available one hour following the live call
and remain available for 30 days. To access the replay, the dial-in
info is as follows:
US Toll
Free:
|
1-877-344-7529
|
International
Toll:
|
1-412-317-0088
|
Canada Toll
Free:
|
855-669-9658
|
Replay Access
Code:
|
10070773
|
End Date: Sep 11, 2015
To access the replay using an international dial-in number,
please select the link below.
https://services.choruscall.com/ccforms/replay.html
Available 1 hour after the end of the conference.
Participants will be required to state their name and company upon
entering the call.
About Organovo Holdings,
Inc.
Organovo designs and creates functional,
three-dimensional human tissues for use in medical research and
therapeutic applications. The Company develops 3D human disease
models through internal development and in collaboration with
pharmaceutical and academic partners. Organovo's 3D human
tissues have the potential to accelerate the drug discovery
process, enabling treatments to be developed faster and at lower
cost. The company recently launched its initial product of the
planned exVive3DTM portfolio offering, a 3D Human
Liver Tissue for use in Toxicology and other preclinical drug
testing. Additional products are in development, with anticipated
release for an exVive3DTM Human Kidney Tissue in
the latter half of calendar year 2016. The Company also actively
conducts early research on specific tissues for therapeutic use in
direct surgical applications. In addition to numerous scientific
publications, the Company's technology has been featured
in The Wall Street Journal, Time Magazine, The Economist,
and numerous other media outlets. Organovo is changing
the shape of medical research and practice. Learn more
at www.organovo.com. Sign up for email updates and
connect with us on Twitter (@Organovo).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/organovo-holdings-inc-announces-fiscal-year-2016-first-quarter-earnings-conference-call-300123867.html
SOURCE Organovo Holdings, Inc.